1 / 12

הוראה בנושאי טיפול תרופתי בסרטן

הוראה בנושאי טיפול תרופתי בסרטן. מאמרים וטקסטים נבחרים ( הרשימה עדיין לא הושלמה) ערך: פרופ’ נ. חיים , מאי 2004 כתובת לשאלות והערות: n_haim@rambam.health.gov.il. Chemotherapy-induced nausea and vomiting. ASCO guidelines…. ESMO guidelines…. NK1 receptor antagonists….

kasia
Télécharger la présentation

הוראה בנושאי טיפול תרופתי בסרטן

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. הוראה בנושאי טיפול תרופתי בסרטן מאמרים וטקסטים נבחרים (הרשימה עדיין לא הושלמה) ערך: פרופ’ נ. חיים , מאי2004 כתובת לשאלות והערות: n_haim@rambam.health.gov.il

  2. Chemotherapy-induced nausea and vomiting • ASCO guidelines…. • ESMO guidelines…. • NK1 receptor antagonists…. • ראה מצגת "מנגנוני פעולה ועמידות של תרופות ציטוטוקסיות ו”תרופות מגינות” לגבי מנגנון פעולה של התרופות השונות.

  3. Chemotherapy-induced nausea and vomiting: ASCO & ESMO Guidelines • Gralla RJ et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines .J Clin Oncol 17: 2971-2994, 1999 • ESMO Minimum Clinical Recommendations , ESMO Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV), April 2002

  4. NK1 receptor antagonists • de Wit R et al. Addition of the oral NK1 antagonist Aprepitant to standard antiemetics provided protection against nausea and vomiting during multiple cycles of cispltin-based chemotherapy. J Clin Oncol 21: 4105-11, 2003 • Hesketh PJ et al. The oral neurokinin-1 antagonist Aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational , randomized , double-blind, placebo-controlled trial in patients receiving high-dose cIsplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 21: 4112-19, 2003 • Kris MG. Why do we need another antiemetic? Just ask. J Clin Oncol 21: 4077-80, 2003 (editorial)

  5. chemotherapy and radiotherapy protectants • ASCO guidelines for the use of mesna, dexrazoxane,and amifostine …. • ראה מצגת "מנגנוני פעולה ועמידות של תרופות ציטוטוקסיות ו”תרופות מגינות” לגבי מנגנון פעולה של התרופות השונות.... • ראה מצגת "פרמקוקינטיקה ומטבוליזם..." לגבי צורות מתן של mesna.

  6. Chemotherapy and radiotherapy protectants-ASCO Guidelines Schuchter LM et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.J Clin Oncol 20: 2895-2903, 2002 : Guidelines for the use of mesna, dexrazoxane, and amifostine….

  7. GCSF • ASCO Guidelines…. • ESMO Guidelines…. • ראה גם מצגת "מנגנוני פעולה של תרופות ציטוטוקסיות ותרופות מגינות"

  8. GCSF-ASCO & ESMO Guidelines • 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. Ozer H et al. for the American Society of Clinical Oncology Growth Factor Expert Panel. J Clin Oncol 18: 3558-3585, 2000. • ESMO Minimum Clinical Recommendations: ESMO Recommendations for the application of hematopoietic growth factors (hGFs)- April 2002

  9. Epoeitin • ASCO Guidelines….

  10. Epoeitin-ASCO Guidelines • Rizzo JD et al. Use of Epoeitin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Hematology. J Clin Oncol 20: 4083-4107, 2002 Guidelines for the use of epoietin in patients with chemotherapy induced anemia….

  11. Bisphosphonates • ASCO Guidelines….

  12. Bisphosphonates-ASCO Guidelines • Hillner BE et al. American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer. J Clin Oncol 21: 4042-57, 2003: Schedule of administration of pamidronate, and zoledronic acid; guidelines for administration in patients with renal dysfunction….

More Related